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Introduction -
One of the hallmarks of human cancer is inappropriate progression through the cell cycle. Under normal circumstances, the cell has numerous checkpoints and mechanisms to ensure that cells do not divide until the genome is fully copied, and that a new cell does not begin copying its DNA until division has finished. DNA replication presents additional challenges, as the process must be tightly coordinated so that the genome is copied accurately, completely, and in a timely fashion.
To this end, cells must recruit a variety of factors to DNA before replication can begin. The first set of proteins to bind the DNA is the Origin Recognition Complex (ORC), a 6 member complex that is thought to recognize the actual replication origins, and then recruit necessary downstream factors. These downstream factors include Cdtl and Cdc6, which in turn recruit the MCM2-7 complex (mini-chromosome maintenance). Once MCM2-7 (thought to be the replicative helicase) is recruited to DNA, a pre replication complex (pre-RC) is formed, and is ready to initiate S-phase pending CyclinE/cdk2 (cyclin dependent kinase 2) activation(I).
Our lab has been interested in the role the ORC plays in mammalian replication. We have previously reported that Orc2 RNA interference (RNAi), in addition to a decrease in chromatin loading of the pre-Replication complex (pre-RC) and overall replication, also causes a strong GI arrest, and cyclin/cdk kinase inhibition. We believed this to be due to an increase in levels of the CDK inhibitor p27. This work had interesting implications for breast cancer: loss of this protective mechanism, in which Orc2 is required for cyclin/cdk kinase activity, and thus, cell cycle progression, may allow cells to replicate in the presence of low pre-RC levels, which may lead to genomic instability via a detrimental S-phase. We have further characterized this protective mechanism in breast cancer cells.
We have previously reported that an Orc2 hypomorphic cell line has a marginal effect on replication in a colon cancer cell line (2) . While this mutation allows genomic replication, it does not allow replication of an Epstein Barr virus (EBV) plasmid. We hypothesize that while the reduction in Orc2 level was sufficient for EBV replication inhibition, a further, acute decrease in ORC proteins is required to affect cellular genomic replication. This funding cycle we have found that these cells do indeed have a subtle defect entering S-phase, similar to what we observe after Orc2 siRNA. However, once the cells enter S-phase, they proceed normally.
Body -1. Characterize the membrane-permeable Cy motif containing peptides that selectively inhibit cyclin/cdk complexes.
Previously reported results on ORC and cell cycle were of continued high interest, so we focused on that work this funding period.
Investigate the Role of Replication Initiation proteins on growth of breast cancer.
We have previously reported that RNAi against Orc2 results in a G 1 arrest with low Cyclin E/Cdk2 activity. This work has been accepted for publication, and is included in the appendix.(3) Briefly, we found that in addition to p27, p21 levels are also increased. This p21 increase appears to be mediated by transcription, but is independent of p53. p27 on the other hand appears to be stabilized at the protein level. When we deplete these proteins together with Orc2, CDK inhibition is relieved. BrDU incorporation (a measure of replication) is also partly rescued, indicating that the CDK inhibition is causing a cell cycle arrest in response to low levels of Orc2. Finally, cells depleted of p21 and p27 with Orc2 show increased apoptosis, which suggests that the cell cycle inhibition is protecting the cells against a an insult, possibly DNA damage. Therefore, the role of Orc2 in CDK cycle activation seems to protect the cells, perhaps by preventing DNA damage resulting from a poor replication cycle with low Orc and pre-RC loading.
In addition to siRNA, we have used a previously generated Orc2 hypomorph cell line. Results in this system have recently been submitted for publication, and are currently undergoing revisions. This cell line expresses a slightly truncated (but active) form of Orc2 in greatly reduced amounts. We have previously shown that pre-RC loading is drastically decreased in these cells, and they have a proliferation defect. In this funding cycle we have further studied the effects of chronic low Orc2 levels on the cell cycle and on chromosomal replication.
Since the cell cycle is prolonged in the Orc2 hypomorph (A/-) cells, we looked for checkpoint activation that may be arresting the cell cycle. We found that Chk2 was phosphorylated on threonine 68 in the A/-cells (Fig. I a) . Although Chk2 can target the Cdc25 family of proteins (phosphatases that activate CDKs), we saw no evidence of this pathway being stimulated. Cdc25c was not phosphorylated in A/-cells, nor was Cdc25A degraded. (Fig l b. ) These proteins usually act to remove inhibitory phosphates from CDK proteins. We examined inhibitory phosphorylation of CDK2, and found that phosphorylation was actually decreased (opposite what we would have expected if Cdc25a was being inhibited by Chk2.) (Fig I c. ) Another important target of Chk2 is p53. We have previously reported that p53 levels are undetectable in this cell line, at both message and protein levels. Although p53 loss was not caused by Orc2 decrease (p53 was lost during the cre-recombination stage, at which point Orc2 protein levels were still normal), the loss of p53 may have allowed the cells to survive in the presence of active Chk2.
Chk2 is usually phosphorylated by ATM (4) (and some cases by ATR). We used siRNA to deplete cells of ATM/ATR, and found that this decreased the level of Chk2 phosphorylation. (Fig I d) . As ATM/ATR are activated by forms of DNA damage, it is possible the A/-cells have higher levels of DNA damage due to low levels of Orc2.
We have previously observed an S-phase decrease in the A/-cells. To study the dynamics of nucleotide incorporation in these cells, we arrested them in nocodazole, and released them. At different timepoints we pulsed with radiolabeled thymidine, and assayed the amount of nucleotide incorporation. We found that the levels of incorporation are significantly less in the A/-cells. (Fig. 2a) The length of G 1 can be determined by the time it takes to reach half maximum incorporation. The A/-cells are also slightly delayed in entering S-phase.
The decrease in nucleotide incorporation could be caused by either difficulty during Sphase, or a failure in S-phase entry. We addressed this by assaying BrDU incorporation on a per-cell basis after nocodazole release using FACS analysis. The A/-cells show a distinct failure to increase the number of BrDU incorporating cells. (Fig. 2b) It appears that the majority of these cells do not enter S-phase. However, if cells are released from S-phase using thymidine/aphidicolin, they are able to incorporate nucleotide normally, which suggests that the cells have trouble moving from G 1 to S, but replicate normally once in S-phase.
Normal progression through G 1 is marked by phosphorylation of Rb, which relieves inhibition of E2F, a transcription factor responsible for upregulating many genes important for cell cycle progression. The A/-cells showed hypo-phosphorylated Rb after release from nocodazole. Further investigation revealed that Cdk2 kinase activity was also significantly decreased in A/-cells. (Fig. 3a) This failure to activate Cdk2 kinase activity could explain the defect in S-phase entry, as Cdk2 kinase activity is required for this transition. When cells are released from an S-phase arrest, Rb is phosphorylated normally, further supporting the notion that once cells can enter S-phase, they are able to proceed normally through the cell cycle. (Fig.   3b) One of the main regulators of CDK activity is the Cyclin binding partner. In G 1 , Cyclin E levels increase, allowing increased Cyclin E/Cdk2 activity. However, Cyclin E levels in A/-cells do not increase as well as controls, which is likely the cause of low Cdk2 activity. (Fig. 3c) . Cyclin E message levels at 3 and 6 hours are very similar to wild type cells, indicating this difference is probably post-transcriptional. (Fig. 3d ) (The mRNA differences at 9 and 12 hours are most likely due to increased E2F activity in the wild type cells, which is caused by Rb inactivation via phosphorylation.) Cyclin E levels could be low due to increased degradation. However, we did not see any decreased Cyclin E stability in the A/-cells, nor did we see any rescue of protein levels followed by inhibition of the proteosome using MG-132. (Fig. 4a,b ) These results suggest that there is a decrease in translation of Cyclin E, although this remains to be tested.
We find it interesting that once A/-cells can enter S-phase, they are able to proceed through the cell cycle, even though Orc2 and pre-RC levels are low. We used DNA combing to further examine origin firing in these cells. Surprisingly, fork density is similar between the cell lines. (Fig. 5a ) Additionally, replication progression is similar between A/-and wild type cells. (Fig. 5b) This suggests that pre-RC loading occurs in vast excess of amounts required for Sphase, supporting the earlier "Jesuit" model of origin firing in which many origins are called, but few are chosen. (5) 3. Increase my knowledge about the biology of breast cancer.
I have continued to learn much about the mechanics of breast cancer. I have read many papers, and attended many seminars dealing with the diseases. In addition, I will attend the Cold Spring Harbor "Eukaryotic DNA replication" meeting in September. As breast cancer and replication (specifically DNA damage repair) are often linked, this meeting will be very informative. 2. Both stories will be presented as a research talk at the Cold Spring Harbor "Eukaryotic DNA Replication" meeting on Sept. 9-11, 2005.
Key Research Accomplishments

Conclusions -
We have now observed a novel role for Orc2 in both breast cancer cells and colon cancer cells. Orc2 is not only required for pre-RC formation and replication, but it seems to be required for activation of Cyclin E/Cdk2 kinase, and therefore, the CDK cycle. In breast cancer cells, Orc2 siRNA reduces Orc2 level, and results in Cyclin E/Cdk2 kinase inhibition, which causes a Gl arrest, preventing further cell cycling. This arrest can be overridden by co-silencing of p21 and p27 together with Orc2. Although these cells are no longer arrested in GI, they show evidence of apoptosis. Under conditions of low Orc2, cells may suffer DNA damage during replication. However, the cell cycle inhibition caused by low Orc2 levels prevents cells from entering a potentially damaging period. This requirement for Orc2 in CDK cycle progression therefore may serve to protect cells, and prevent S-phase entry until Orc2, and thus pre-RC, levels are sufficient.
We have previously generated an Orc2 hypomorph cell line in colon cancer cells. We returned to this system to further study the role of Orc2 in CDK cycle progression. We found that although these cells are able to proliferate and survive, there is strong evidence that the same requirement for Orc2 exists. When cells are synchronized in GI, we observe a failure to activate Cyclin E/Cdk2, which results in a large number of cells failing to enter S. Those cells that do enter S seem to proceed normally, despite low levels of Orc2 and pre-RC. This indicates that the primary role of Orc2 may be CDK cycle activation, which could serve to prevent replication with low pre-RC loading. When Orc2 levels are low, these cells have an activated DNA damage checkpoint, but it appears as if the checkpoint signal transduction is non-functional, as p53 is not expressed in these cells. This absence of p53 is likely important for the survival of these cells despite the active checkpoint. It is also interesting that a subpopulation of the cells is able to survive despite kinase inhibition. This could be due to higher basal levels of Cyclin E in the colon cancer cells. Although kinase activity is reduced, there may be enough residual Cyclin E/Cdk2 activity to allow some cells to enter S-phase, and continue to proliferate.
These results illustrate that breast cancer cells with normal levels of Cyclin E depend upon Orc2 for CDK cycle progression, and thus, cell cycle progression. However, our results suggest that if Cyclin E levels were elevated (as can happen in cancerous cells), this protective mechanism would no longer function to arrest the cell cycle. Although the cells may at that time activate a DNA damage checkpoint, mutations in such pathways are common (although the line we used is p53 wild type, several breast cancer cell lines are mutant for p53.) Without the DNA damage checkpoints, together with possible additional damage from low Orc2 replication, the mutagenic potential for such cells would be greatly increased, potentially leading to more dangerous forms of cancer. 
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Gylin E wo D. The origin recognition complex (ORC) is involved in in cell cycle arrest after DNA damage. p53 activation by checkformation of prereplicative complexes (pre-RCs) on point pathways induces p21 transcription to inhibit cell cycle replication origins in the G, phase. At the G,/S transiprogression, but there are several p53-independent pathways tion, elevated cyclin E-CDK2 activity triggers DNA rep-for inducing p21 mRNA (8). lication to enter S phase. The CDK cycle works as an Initiation of DNA replication first requires the assembly of engine that drives progression of cell cycle events by prereplicative complexes (pre-RCs)l at origins of DNA replisuccessive activation of different types of cyclin-CDK. cation during the G, phase (9) . Origin recognition complex However, how the CDK cycle is coordinated with rep-(ORC) is a six-subunit complex required to mark the origins lication initiation remains elusive. Here we report that of DNA replication. In late M and early G, phases, CDC6 and acute depletion of ORC2 by RNA interference (RNAi)
CDT1 are recruited to origins in an ORC-dependent fashion arrests cells with low cyclin E-CDK2 activity. This re-followed by chromatin-loading of MCM2-7 complexes to form sult suggests that loss of a replication initiation pro-pre-RCs (10). Elevated activity of CDK2 at GjS promotes tein prevents progression of the CDK cycle in G 1 . p27 pre-ing (0 Elevated actiity of CDK2 at G riS p o and p21 proteins accumulate following ORC2 RNAi loading of initiation proteins such as CDC45 on origins to and are required for the CDK2 inhibition. Restoration initiate DNA replication (9) . Activation of cyclin E-CDK2 is of CDK activity by co-depletion of p27 and p21 allows believed to be independent of the amount of replication inimany ORC2-depleted cells to enter S phase and go on tiator proteins. In this paper, however, we found that depleto mitosis. However, in some cells the release of the tion of one of the replication initiation proteins results in G, CDK2 block caused catastrophic events like apoptosis.
arrest with low cyclin E-CDK2 activity. Cell cycle progression Therefore, the CDK2 inhibition observed following was halted by inhibition of cyclin E-CDK2 by p27 and p21 ORC2 RNAi seems to protect cells from premature S accumulation. These results suggest a requirement of repliphase entry and crisis in DNA replication. These re-cation proteins for CDK2 activation and provide a link besults demonstrate an unexpected role of ORC2 in CDK2 tween CDK2 and initiation proteins that couples cell cycle activation, a linkage that could be important for main-progression to replication initiation. taining genomic stability.
EXPERIMENTAL PROCEDURES
Cell Culture and RNAi-Cells were cultured under standard growth The CDK cycle governs the sequence of cell cycle events by condition. For siRNA transfection, cells were grown at -50% confluence in a 6-well plate and transfected at 24-h intervals with 0.24 nmol of successively phosphorylating proteins that trigger essential annealed siRNA duplex (Dharmacon Research) using Oligofectamine processes of cell proliferation such as DNA replication and (Invitrogen). Six hours after the first transfection, cells were split 1:2 to mitosis (1-3). In addition to binding to cyclins, the activity of maintain the cells in log phase. Target sequences of oligonucleotides CDK is regulated by its phosphorylation. Removal of the inhib-used were as follows: ORC2-A, AAGAAGGAGCGAGCGCAGCUU; itory phosphorylation of Thr 14 and TyrfO of CDK by Cdc25 ORC2-B, GAUCAGCUAGACUGGAUAGUA; p27-A, AAGGUUGCAUAphosphatase and phosphorylation of the T-loop by CDK-acti-CUGAGCCAAG; p21-A, AACAUACUGGCCUGGACUGUU; p53-A, AA-GACUCCAGUGGUAAUCUAC; control, AACGUACGCGGAAUACUUvating kinase are also required for CDK2 activity (4). Activities CGA. of G 1 and S phase cyclin-CDK complexes are also regulated by
Western and Northern Blotting-ORC3, ORC4, and ORC6 antibodies binding to CDK inhibitor proteins such as p27 and p21 (5). p 2 7 were described earlier (11-13). Rabbit antibodies against ORC1 and protein levels are high in Go and G 1 phases to maintain low ORC5 were raised using His6-tagged recombinant proteins, ORC1 CDK activity. Proteasome-mediated degradation following (220-831) and ORC5 (75-686). Anti-p27 (C-19), anti-p21 (C-19), antiubiquitinylation by SCFskp2 complex is responsible for the low MCM7 (141.2), anti-cyclin E (HE12), anti-cyclin A (H-432), anti-cyclin B (H-433), and anti-CDK2 (M2) antibodies were purchased from Santa levels of p27 protein during S-G 2 phases (6). p 2 7 is also ubiq-Cruz Biotechnology. Anti-ORC2 and anti-3-actin antibodies were puruitinylated by KPC1 and degraded by proteasome upon cell chased from BD Biosciences and Sigma, respectively. Anti-p53 antibody cycle entry (7) . On the other hand, p21 plays an important role was obtained from Cell signaling technology. Anti-pRB antibody was the kind gift of Dr. E. Harlow. Cellular total RNA was purified using the RNeasy Midi kit (Qiagen). * This work was supported by Grants RO1 CA60499 and DAMD Immunoprecipitation and Kinase Assay-Cells were lysed in 50 mM 17-00-1-0166 and DAMD 17-01-1-0163 from the United States Army Tris-HC1 (pH 7.4), 150 mm NaCI, 0.1% Nonidet P-40, 5 mm EDTA, 50 Breast Cancer Research Program. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 'The abbreviations used are: pre-RC, prereplicative complex; Br-U.S.C. Section 1734 solely to indicate this fact.
dUrd, 5-bromo-2'-deoxyuridine; CDK, cyclin-dependent kinase; ORC, $ To whom correspondence should be addressed: Dept. of Biochemis-origin recognition complex; RNAi, RNA interference; siRNA, small try and Molecular Genetics, University Damage Checkpoints-To test whether DNA damage or DNA with anti-p-actin antibody as a loading control. C, messenger RNA replication checkpoint pathways were activated upon acute levels of ORC1-6 following ORC2-A RNAi. MCF10A cells were transdepletion of ORC2, phosphorylation of Chkl on Ser 1 7 and fected with control or ORC2-A siRNAs for 72 h and mRNA levels of six Chk2 on Thres were examined (Fig. IF) . Those residues are ORC subunits analyzed by Northern blotting. The blot was also probed for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a loading MCF10A cells were transfected with control and ORC2-A siRNAs. Cells Cyclin E-associated Kinase Activity Is Inhibited in ORC2-were stained with propidium iodide after 72 h and then analyzed by depleted Cells-Activation of cyclin E-CDK2 at G1/S was exflow cytometer. F, besides transfection with control or ORC2-A siRNAs, cells were also cultured with or without 10 mm hydroxyurea (HU) or 0. 5 pected not to be affected by loss of an initiator protein. Surpris-AM daunorubicin for 5 h. Cell extracts were analyzed by Western blotingly, in vitro kinase assays with immunoprecipitated proteins ting with antibodies against indicated proteins, revealed that cyclin E-associated kinase was inhibited after 36-h treatment with ORC2-A RNAi ( Fig. 2A) . RNAi against p53 mmo NaF, 1 mam NaYVO.,, and protease inhibitor mixture (Sigma). For did not have such an effect, suggesting that the inhibition of kinase assay, equal amounts of cell lysates (100 gg) were immunoprecyclin E-CDK2 activity is not a nonspecific effect due to acticipitated with anti-CDK4 (C-22), anti-cyclin E (HElll), anti-cyclin A (H-432), or anti-cyclin B1 (H-433) antibodies (Santa Cruz Biotechnolvation of RNA interference pathway. After 72 h, ORC2-deogy). In vitro kinase assay was carried out using recombinant pRB-C pleted cells accumulate with 2N DNA content in the FACS and bistone HI as substrates as described previously (14).
analysis (Fig. lE) . We therefore examined where the CDK cycle BrdUrd Imrmunostaining and FACS Analyses-Cells were treated is arrested in those cells. Examination of cyclin levels by imwith 10 gm BrdUrd (Sigma), fixed with 4% paraformaldehyde, permemunoblotting showed that the cells are arrested with high abilized with 0.3% Triton X-100, and stained with anti-BrdUrd antibody containing nuclease (Amersham Biosciences) diluted in 3% bovine cyclin D1 and cyclin E levels (Fig. 2B) . In vitro kinase assays serum albumin (1:2) for 45 min at room temperature. After rinsing with revealed that, although CDK4 kinase activity was unchanged, phosphate-buffered saline three times, cells were incubated with cyclin E-CDK2 activity is inhibited in these cells (Fig. 2C) . TRITC-conjugated anti-mouse IgG antibody (Pierce) diluted in 3% bo-Inhibition of cyclin E-CDK2 activity would account for the vine serum albumin (1:500). Percentage of cells incorporating BrdUrd cyclin E accumulation seen in Fig. 2B due to a decrease in its was calculated as an average of three samples. FACS analysis for DNA autophosphorylation and ubiquitiuylation (18, 19). Considering content was performed as described (15) . Percentages of cells in G 0 , S, and GJM phases were calculated using ModiFit.
the accumulation of cyclin E protein, the decrease in the specific activity of cyclin E-associated kinase was even greater RESULTS than the 70% seen in Fig. 2C . The increase of cyclin D1 protein
DNA Synthesis Is Reduced in ORC2-depleted Cells-ORC2
is after 72 h could be due to arrest of the CDK cycle in G, phase a part of the core of the origin recognition complex (15) . Upon where the level of the protein is high. In contrast to G, cyclins, RNAi targeting ORC2 in MCF10A breast epithelial cells, ORC2 cyclin A and cyclin B1 levels were low in ORC2-depleted cells protein levels were decreased (Fig. 1A) . Two siRNA oligonuafter 72 h (Fig. 2B) , accounting for the low kinase activity in the •.~p~ mulation of p27 and p21 after ORC2 RNAi. MCF10A cells were transsiRNA oligos for the indicated time. A, cyclin E-associated kinase acfected with the indicated siRNA duplexes for 72 h and p27 and p21 tivity after RNAi with indicated siRNAs. Extracts were prepared from proteins analyzed by Western blotting. B, accumulation of p27 and p21 cells after 36 h and used for in vitro kinase assay using anti-cyclin E proteins in WI-38 following ORC2-A RNAi. Cells were transfected by antibody and Western blot for indicated proteins. B, cyclin levels after control or ORC2-A siRNAs for 72 h and the indicated proteins analyzed ORC2-A RNAi (72 h). Cell extracts were prepared and analyzed hy by Western blotting. C, time course analysis of ORC2, p27, p21, cyclin Western blotting for indicated proteins. C, kinase activities of cyclin-E-associated kinase activity, pRB, and MCM7 after ORC2 RNAi. CDKs after ORC2-A RNAi (72 h). Equal amounts of cell extracts (100 gg MCF10A cells were transfected with control or ORC2-A siRNA oligoof proteins) were subjected to an in vitro kinase assay using antibodies nucleotides. Cell extracts were prepared at the indicated times and against indicated proteins. Three independent in vitro kinase assays analyzed by Western blotting for indicated proteins. Equal amounts of were quantitated by a Phosphorlmager, and the average is shown. D, cell extracts (100 g~g of proteins) were also subjected to an in vitro phosphorylation status of pRB in ORC2-depleted cells. Extracts of the kinase assay using anti-cyclin E antibody. D, cyclin E-associated p27 cells transfected with indicated siRNAs (72 h) were analyzed by Westprotein in ORC2-depleted cells. Extracts of the MCF10A cells transern blotting for pRB. E, messenger RNA levels of cyclin E and cyclin A fected with control and ORC2-A siRNA were prepared after 36 h and after ORC2-A RNAi (72 h). Total RNA was extracted, and expression of subjected to immunoprecipitation (IP) using anti-cyclin E antibody. The the indicated genes was analyzed by Northern blotting. GAPDH, glyc-amount of the indicated proteins in cell lysates and immunoprecipitaeraldehyde-3-phosphate dehydrogenase.
tion was assessed by Western blotting. The asterisk marks the ][g light chain. RyA, cyclin.
in vitro kinase assay using anti-cyclin A and anti-cyclin B1 ensure that the p27 and p21 responses wore not unique to the antibodies (Fig. 2C) . breast epithelial cell line MCFt0A, ORC2 was depleted in pRB was hypophosphorylated in cells transfected with ORC2 WI-38 primary lung fibroblasts. p27 and p21 accumulation was siRNAs, confirming that CDK2 is inhibited in vivo (Fig. 2D) .
also observed in WI-38 (Fig. 3B) . The hypophosphorylated form of pRB binds E2F and works as Since p27 is targeted for degradation after phosphorylation a co-suppressor for E2F-regulated genes (20) . It was reported by cyclin E-CDK2 (23, 24), we wanted to ensure that the p27 that partial phosphorylation of pRB by cyclin D-CDK4/6 reaccumulation was not a secondary effect of CDK2 inhibition. A lieves the suppression of cyclin E promoter, allowing cyclin E time course study was performed to determine whether p27 expression. Consistent with the unchanged activity of cyclin accumulation preceded or followed cyclin E-CDK2 inhibition. D-CDK4, cyclin E mRNA was not decreased in ORC2 RNAiAfter ORC2-A RNAi p27 starts to accumulate as early as 24 h, treated cells (Fig. 2E) . Further phosphorylation of pRB by in parallel with the decrease in ORC2 protein (Fig. 3C) and cyclin E-CDK2 is required for relieving cyclin A promoter supbefore the inhibition of cyclin E-CDK2 kinase activity or hypression by pRB (21, 22). Decrease in cyclin E-CDK2 activity pophosphorylation of RB. After 36 h, p27 levels increase furtherefore explains the decrease in cyclin A mRNA, cyclin A and ther, and cyclin E-associated kinase activity decreases. At this B1 protein levels, and kinase activities (Fig. 2 , B, C, and E). In time point, more p27 is associated with cyclin E (Fig. 3D, lane summary, the CDK cycle is inhibited at the step of cyclin 2). Therefore, p27 accumulation precedes cycain E-CDK2 inhi-E-CDK2 activation in ORC2-depleted cells. bition and could be the cause rather than the effect of CDK2 ORC2 Depletion Results in Accumulation of CDK Inhibitors inhibition. Consistent with the decrease in cyclin E-CDK2 acp27 and p21-We next explored how cyclin E-CDK2 activity is tivity, hypophosphorylated pRB appeared at the 36-h tise inhibited in ORC2-depleted cells. Two CDK inhibitors, p27 and point. MCM7, encoded by an E2F-regulated gene, starts to p21, were accumulated in MCF10A cells after decreasing ORC2 decrease after 48 h. These results suggest that p27 increase is level by two different siRNA oligonucleotides (Fig. 3A) . To an early response to ORC2 depletion and is not secondary to cleotides eliminates p21 and p27 accumulation after ORC2 RNAi. points. p27 levels in proteins from control and ORC2 RNAi-treated cells MCF10A cells were transfected with p21 and/or p27 siRNAs for 24 h (75 and 40 Ag, respectively) were examined by Western blotting. The before transfection with control or ORC2-A. After 48 h cell lysates were blot fbr control RNAi was exposed two times longer than the one for harvested and immunoblotted for indicated proteins. Equal amounts of ORC2 RNAi to get the same intensity for the p27 protein bands at the cell extracts (100 tg of proteins) were also used for immunoprecipita-0 h time point. C, quantitation of p27 protein levels after cycloheximide tion and subjected to an in vitro kinase assay using pRB-C as a subtreatment. Intensity of p27 bands in B was quantitated, and the rela-strate. Coomassie Brilliant Blue staining of pRB-C protein is shown. B, tive intensity to that seen at the 0 h time point is shown. D, p5 3 -relative levels of in vitro cyclin E-CDK2 kinase activity. The "'P incorindependent induction of p21 after ORC2 RNAi. MCF10A cells were porated into the substrate in the in vitro kinase assay in A was quantransfected with control or p53 siRNAs for 48 h before transfection with titated by a Phosphorhmager and was normalized to that seen with control or ORC2-A siRNAs (48 h). Protein levels of ORC2 and p53 and control cells treated with control siRNA oligonucleotides. mRNA levels of p21 were assessed by Western and Northern blotting, respectively. mechanism. Consistent with the idea that the general p53 the decrease in CDK2 kinase activity. Once CDK2 kinase acpathway is not activated after ORC2 RNAi, another p53-regutivity is inhibited, suppression of E2F by pRB leads to further lated gene, PIG3 (25), was not induced after ORC2 RNAi suppression of other S phase activators like MCM7 and (Fig. 4A) . cyclin A.
p27 and p21 Inhibit Cyclin E-CDK2 following ORC2 DepleAfter ORC2 RNAi the p21 level also starts to increase at 24 h tion-To test whether p 2 7 and p21 are responsible for the and reaches the maximum at 36 h time point, when cyclin inhibition of cyclin E-CDK2 following ORC2 depletion, we per-E-CDK2 becomes inactive (Fig. 3C) . This is much before the formed RNAi against p27 and/or p21 prior to ORC2 RNAi. time point when secondary effects of the cell cycle arrest be-When p27 or p21 alone are depleted, cyclin E-CDK2 activity come evident as revealed by MCM decrease at 48 h, suggesting was only partially restored after ORC2 RNAi (Fig. 5A , lanes 4 that p21 elevation could also be a cause (rather than effect) of and 6). However, when both p27 and p21 are depleted prior to cyclin E-CDK2 inhibition after ORC2 depletion.
ORC2 RNAi, the cyclin E-CDK2 activity was restored almost to p27 Protein Is Stabilized, and p21 mRNA Is Induced after the control level in ORC2-depleted cells (Fig. 5A, lane 8 , and ORC2 Depletion-We next sought the mechanism of p27 and Fig. 5B ). This result indicates that the induction of p21 and p 2 7 p21 accumulation. p27 mRNA does not increase in the ORCis critical for inhibition of CDK2 after ORC2 depletion. depleted cells suggesting that regulation of the protein is at the Inhibition of DNA Synthesis after ORM2 Depletion Is Caused post-transcriptional level (Fig. 4A) . After 26-h treatment of Partly by CDK2 Inhibition-Restoration of cyclin E-CDK2 ac-ORC2 RNAi, cycloheximide was added to block new protein tivity in ORC2-depleted cells by co-depletion of p21 and p27 synthesis and the rate of decrease of p27 protein examined prompted us to test if CDK2 inhibition contributes to inhibition (Fig. 4, B and C) . Quantitation of p27 protein levels revealed of DNA synthesis after ORC2 depletion. Cells transfected with that the half-life of p27 was increased from 1.4 h to 5.6 h in p21 and p27 siRNAs were treated with ORC2 RNAi and ORC2 RNAi-treated cells, indicating that p27 is stabilized after BrdUrd incorporation measured by immunostaining using ORC2 RNAi.
anti-BrdUrd antibody. BrdUrd-positive cells decreased by 80% In contrast to p27, the mRNA level of p21 was increased after after ORC2 RNAi ( Fig. 6A and 6B ). Pretreatment with p 2 l and 36-h treatment of ORC2 RNAi (Fig. 4A ). p53 is a well known p27 siRNAs increased BrdUrd-positive cells after ORC2 RNAi, inducer of p21 in response to DNA damage. We tested involveindicating that part of the inhibition of DNA synthesis followment of p53 in the p21 induction by sequential transfection of ing ORC2 depletion is caused by CDK2 inhibition but not by siRNAs against p53 and ORC2. Although pretreatment of cells decrease in ORC2 protein levels. Furthermore, there is a 15-with p53 siRNA reduced p53 to lower than basal level, p21
fold increase in the number of ORC2-depleted cells that enter mRNA was still increased by ORC2 RNAi (Fig. 4D) . This result mitosis when p27 and p21 are removed (Fig. 6C) , supporting suggests that p21 expression is induced by a p53-independent the notion that some ORC2-depleted cells are arrested by CDK
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Linkage between ORC and CDK2 Activation 
DISCUSSION
in a normal cell cycle, pre-RC formation is completed during the G, phase, and cyclin E-CDK2 activation triggers replication initiation and In this study we discovered that progression of the CDK cycle S phase entry. B, in ORC2-depleted cells CDK activation at G./S is is prevented after depletion of one of the replication initiation inhibited by both p27 and p21. Accumulation of p27 and p21 proteins proteins, ORC2. ORC2-depleted cells are arrested in G 1 phase could be the active checkpoint mechanism to prevent CDK activation in response to low levels of ORC or pre-RCs. Alternatively, accumulation through inhibition of cyclin E-CDK2 (Fig. 7) . Since initiation of of these proteins is due to an obligate role of ORC in the regulation of DNA replication defines S phase (S for synthesis), one might these proteins (see "Discussion" for details). say that cells are in G, phase when DNA replication is inhibited by ORC2 RNAi. Since CDK activity is low in the G, phase, gress to mitosis, although we cannot distinguish whether the one might therefore jump to the conclusion that CDK activity is recovered DNA replication is from initiation at new origins or low after ORC depletion simply as a reflection of the cell cycle from elongation of pre-existing forks. Given that cancer cells stage. However, this logic is not correct because CDK activation can proliferate with less than 10% of ORC2 levels (16), we are at G1/S is expected to occur regardless of ORC amount. For not surprised to discover that many of the cells in the populaexample, yeast Ore mutants activate CDK even when replication have sufficient ORC2 for a normal S phase once the CDK tion initiation fails, leading to activation of DNA damage cycle is de-repressed. However, apoptosis was observed in some checkpoint pathways or even premature entry into mitosis with of the cells, suggesting that CDK inhibition in ORC2-depleted unreplicated DNA (27) (28) (29) (30) . Therefore, the CDK2 inhibition cells can prevent catastrophic events due to premature S phase that is seen following ORC2 depletion is unexpected and entry with fewer functional origins. In nearly 50% of the cells unique to higher eukaryotes. We suggest that the linkage be-DNA synthesis was not restored despite the restoration of tween ORC function and CDK2 activation has evolved to pre-CDK2 activity, suggesting that in these cells the ORC2 levels vent such premature progression of the mammalian cell cycle, were genuinely below a threshold sufficient for DNA replica-CDK inhibition following ORC2 RNAi is due to accumulation tion. We think that differences in levels of residual ORC2 in of p27 and p21. p 2 7 and p21 accumulation is a cause of CDK various cells in the population account for the differences in the inhibition rather than a result of G 1 arrest, since knock-down of responses after de-repression of CDK2. p27 and p21 restores CDK activity in ORC2-depleted cells. Checkpoint Activation or Obligate Role of ORC in the CDK RNAi decreases ORC2 in the entire population of cells to less Cycle-There are two possible interpretations for the inhibition than 10% of wild type levels, but there are bound to be variaof cyclin E-CDK2 activity in ORC-depleted cells. The first is tions in the extent of depletion between cells in the population.
that ORC is not normally required for CDK2 activation, but Indeed DNA synthesis was partially restored when CDK activabnormally low levels of ORC activate emergency checkpoint ity is recovered in ORC2-depleted cells. In many of the cells, pathways that prevent cyclin E-CDK2 activation and arrest the DNA replication was normal enough to allow the cells to procell cycle in G 1 . The second possibility is that ORC has an obligate role in the normal activation of cyclin E-CDK2 even linkage between ORC and CDK2 activation in human cells. In during the normal cell cycle. In this possibility, ORC-depleted retrospect, such a linkage seems essential for maintaining cells fail to activate cyclin E-CDK2 resulting in cell cycle arrest genomic stability. As a part of the mechanism to prevent rein G 1 . We cannot at present distinguish between these possi-replication, pre-RC formation is allowed only when CDK activbilities. Dissecting mechanisms linking p21 and p27 accumu-ity is low (40) (41) (42) . Therefore premature activation of CDK2 lation to ORC2 depletion will help determine whether this is an before sufficient origins are licensed would further inhibit emergency checkpoint mechanism or an obligate role of ORC in pre-RC formation and irreversibly push the cells into S phase. p21 and p27 regulation. Replication initiation from fewer origins might lead to chromoCheckpoint-like Mechanism at G,/S-Cell cycle checkpoint is somal damage as seen in the yeasts (43-45). Thus, ORC-dedefined as a mechanism preventing initiation of the next step pendent activation of CDK2 could have evolved to protect the until the previous step is complete (31) . Since activation of mammalian cell from genetic instability resulting from premacyclin E-CDK2 triggers initiation of DNA replication in the ture activation of CDK2. ORC protein levels are low in quiesnormal situation, the fact that cyclin E-CDK2 is inhibited in cent tissues (46) so that cells emerging from quiescence have to response to low levels of ORC seems to fit with the idea of a cell accumulate ORC in preparation for the first S phase. It is cycle checkpoint. Consistent with this, restoration of CDI2 interesting to speculate that by overriding the linkage between activity in ORC2-depleted cells by p27 and p21 RNAi lets the ORC abundance and cyclin E-CDK2 activity, overexpression of cell cycle progress into S phase or induce apoptosis. p21 and cyclin E is particularly deleterious to cells as they emerge from p27 are therefore effectors in a checkpoint pathway that pre-quiescence. Consistent with this, overexpression of cyclin E vent initiation of DNA replication until G 1 events dependent on induces chromosomal instability in mammalian cells (47), and ORC function are complete. Alternatively, the checkpoint path-many human tumors overexpress cyclin E (48). Recently, it was way might sense the ORC2 level directly. However, since ORC2 shown that pre-RC formation was severely impaired in cells protein levels are unchanged during the cell cycle, we think it expressing cyclin E at high levels (49) , suggesting the impormore likely that failure to complete G, events involving ORC is tance of proper regulation of cyclin E-CDI2 activity for chrosomehow sensed to prevent premature entry into S phase. mosome stability. Consistent with this, blocking pre-RC assembly by overexpres-
The recent creation of viable mice with CDK2 deletion raises sion of a stable form of geminin in primary cells inhibits CDK questions as to whether CDK2 has an essential role in mainleading to the appearance of hypophosphorylated pRB (32). malian cells (50, 51) . The yeast CDK is, however, essential for Thus, it is possible that formation of pre-RCs is linked to CDK G 1 1S transition and plays a critical role in maintaining genomic activation and allows cells to enter S phase once enough pre-stability by preventing re-replication in one cell cycle. We RCs are formed. Normally p27 is transiently stabilized in early therefore favor the hypothesis that the firing of origins and the G, phase and degraded in late G, once CDK2 is active. Since prevention of re-replication both require CDK2 in mammals, this period of p27 stabilization overlaps with the time for but these actions are executed by one of the other mammalian prc-RC formation, we speculate that degradation of p27 is CDKs in the CDK2 null mice. Thus, we believe that the recoupled to pre-RC formation.
quirement of ORC for the proper activation of CDK2 is likely to ORC Function in p27 Degradation-Xicl, a Xenopus homo-be an important feature of cell cycle control and genomic stalog of p27, is ubiquitinylated by SCFskp 2 at origins of DNA bility for mammalian cells in vivo.
Finally, recent studies (37, 52, 53) have implicated ORC in replication in egg extracts and ORC depletion from extracts miocfutonlkehr os ecndsaonndsggstabilizes Xicl (33, 34) . The stabilization of human p27 after tin Thecesuls rpte hr e a ddntothe cellula repat ORC depletion is consistent with this result. However, at the andd adfunctions that are dependent on ORC and extend the earliest time point when p27 is stabilized (24-36 h), we did not intercnction betwe en ORG and oep en the see any decrease in the chromatin association of Skp2 (data not shown). Although the exact mechanism of p27 stabilization is cycle machinery. unclear, we are currently entertaining two hypotheses. When
